Glass House Brands Inc.

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, IPSEY has a market cap of 64.9B. Regarding current trading prices, GLASF is priced at $9.65, while IPSEY trades at $49.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas IPSEY's P/E ratio is 31.46. In terms of profitability, GLASF's ROE is -0.23%, compared to IPSEY's ROE of +0.10%. Regarding short-term risk, GLASF is less volatile compared to IPSEY. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check IPSEY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, MKKGY has a market cap of 55.7B. Regarding current trading prices, GLASF is priced at $9.65, while MKKGY trades at $25.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas MKKGY's P/E ratio is 18.18. In terms of profitability, GLASF's ROE is -0.23%, compared to MKKGY's ROE of +0.09%. Regarding short-term risk, GLASF is more volatile compared to MKKGY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check MKKGY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, MKGAF has a market cap of 54.5B. Regarding current trading prices, GLASF is priced at $9.65, while MKGAF trades at $132.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas MKGAF's P/E ratio is 17.82. In terms of profitability, GLASF's ROE is -0.23%, compared to MKGAF's ROE of +0.09%. Regarding short-term risk, GLASF is less volatile compared to MKGAF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check MKGAF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TKPHF has a market cap of 50.6B. Regarding current trading prices, GLASF is priced at $9.65, while TKPHF trades at $32.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TKPHF's P/E ratio is 72.77. In terms of profitability, GLASF's ROE is -0.23%, compared to TKPHF's ROE of +0.02%. Regarding short-term risk, GLASF is more volatile compared to TKPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check TKPHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HLNCF has a market cap of 43B. Regarding current trading prices, GLASF is priced at $9.65, while HLNCF trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HLNCF's P/E ratio is 19.36. In terms of profitability, GLASF's ROE is -0.23%, compared to HLNCF's ROE of +0.06%. Regarding short-term risk, GLASF is more volatile compared to HLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HLNCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SDZNY has a market cap of 34.6B. Regarding current trading prices, GLASF is priced at $9.65, while SDZNY trades at $83.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SDZNY's P/E ratio is 38.23. In terms of profitability, GLASF's ROE is -0.23%, compared to SDZNY's ROE of +0.08%. Regarding short-term risk, GLASF is more volatile compared to SDZNY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SDZNY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TEVJF has a market cap of 34B. Regarding current trading prices, GLASF is priced at $9.65, while TEVJF trades at $29.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TEVJF's P/E ratio is 24.12. In terms of profitability, GLASF's ROE is -0.23%, compared to TEVJF's ROE of +0.21%. Regarding short-term risk, GLASF is more volatile compared to TEVJF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check TEVJF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TAIPY has a market cap of 18.1B. Regarding current trading prices, GLASF is priced at $9.65, while TAIPY trades at $14.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TAIPY's P/E ratio is 82.35. In terms of profitability, GLASF's ROE is -0.23%, compared to TAIPY's ROE of +0.02%. Regarding short-term risk, GLASF is less volatile compared to TAIPY. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check TAIPY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, GLASF is priced at $9.65, while ESALY trades at $61.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ESALY's P/E ratio is 20.54. In terms of profitability, GLASF's ROE is -0.23%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, GLASF is less volatile compared to ESALY. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check ESALY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SGIOY has a market cap of 16.8B. Regarding current trading prices, GLASF is priced at $9.65, while SGIOY trades at $9.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SGIOY's P/E ratio is 15.67. In terms of profitability, GLASF's ROE is -0.23%, compared to SGIOY's ROE of +0.14%. Regarding short-term risk, GLASF is more volatile compared to SGIOY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SGIOY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, BIOVF has a market cap of 16.4B. Regarding current trading prices, GLASF is priced at $9.65, while BIOVF trades at $47.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas BIOVF's P/E ratio is 169.11. In terms of profitability, GLASF's ROE is -0.23%, compared to BIOVF's ROE of +0.02%. Regarding short-term risk, GLASF is more volatile compared to BIOVF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check BIOVF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SGIOF has a market cap of 16.3B. Regarding current trading prices, GLASF is priced at $9.65, while SGIOF trades at $19.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SGIOF's P/E ratio is 15.16. In terms of profitability, GLASF's ROE is -0.23%, compared to SGIOF's ROE of +0.14%. Regarding short-term risk, GLASF is less volatile compared to SGIOF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check SGIOF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, IPSEF has a market cap of 9.4B. Regarding current trading prices, GLASF is priced at $9.65, while IPSEF trades at $113.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas IPSEF's P/E ratio is 18.07. In terms of profitability, GLASF's ROE is -0.23%, compared to IPSEF's ROE of +0.12%. Regarding short-term risk, GLASF is less volatile compared to IPSEF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check IPSEF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ESALF has a market cap of 8.5B. Regarding current trading prices, GLASF is priced at $9.65, while ESALF trades at $30.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ESALF's P/E ratio is 27.27. In terms of profitability, GLASF's ROE is -0.23%, compared to ESALF's ROE of +0.05%. Regarding short-term risk, GLASF is less volatile compared to ESALF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check ESALF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ESAIY has a market cap of 8.4B. Regarding current trading prices, GLASF is priced at $9.65, while ESAIY trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ESAIY's P/E ratio is 27.41. In terms of profitability, GLASF's ROE is -0.23%, compared to ESAIY's ROE of +0.05%. Regarding short-term risk, GLASF is more volatile compared to ESAIY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check ESAIY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SFOSF has a market cap of 6.9B. Regarding current trading prices, GLASF is priced at $9.65, while SFOSF trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SFOSF's P/E ratio is 13.68. In terms of profitability, GLASF's ROE is -0.23%, compared to SFOSF's ROE of +0.09%. Regarding short-term risk, GLASF is more volatile compared to SFOSF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SFOSF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, GZPHF has a market cap of 6.2B. Regarding current trading prices, GLASF is priced at $9.65, while GZPHF trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas GZPHF's P/E ratio is 9.00. In terms of profitability, GLASF's ROE is -0.23%, compared to GZPHF's ROE of +0.08%. Regarding short-term risk, GLASF is more volatile compared to GZPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check GZPHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, LVZPF has a market cap of 6.1B. Regarding current trading prices, GLASF is priced at $9.65, while LVZPF trades at $5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas LVZPF's P/E ratio is 15.35. In terms of profitability, GLASF's ROE is -0.23%, compared to LVZPF's ROE of +0.14%. Regarding short-term risk, GLASF is less volatile compared to LVZPF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check LVZPF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HLBBF has a market cap of 5.3B. Regarding current trading prices, GLASF is priced at $9.65, while HLBBF trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HLBBF's P/E ratio is 13.04. In terms of profitability, GLASF's ROE is -0.23%, compared to HLBBF's ROE of +0.13%. Regarding short-term risk, GLASF is more volatile compared to HLBBF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HLBBF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HLUBF has a market cap of 4.8B. Regarding current trading prices, GLASF is priced at $9.65, while HLUBF trades at $4.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HLUBF's P/E ratio is 9.64. In terms of profitability, GLASF's ROE is -0.23%, compared to HLUBF's ROE of +0.13%. Regarding short-term risk, GLASF is less volatile compared to HLUBF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check HLUBF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, DNPUF has a market cap of 4.5B. Regarding current trading prices, GLASF is priced at $9.65, while DNPUF trades at $11.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas DNPUF's P/E ratio is 4.68. In terms of profitability, GLASF's ROE is -0.23%, compared to DNPUF's ROE of +0.49%. Regarding short-term risk, GLASF is more volatile compared to DNPUF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check DNPUF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SMDPY has a market cap of 4.5B. Regarding current trading prices, GLASF is priced at $9.65, while SMDPY trades at $11.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SMDPY's P/E ratio is 4.61. In terms of profitability, GLASF's ROE is -0.23%, compared to SMDPY's ROE of +0.49%. Regarding short-term risk, GLASF is more volatile compared to SMDPY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SMDPY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SGFEF has a market cap of 4.4B. Regarding current trading prices, GLASF is priced at $9.65, while SGFEF trades at $100.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SGFEF's P/E ratio is 20.53. In terms of profitability, GLASF's ROE is -0.23%, compared to SGFEF's ROE of +0.16%. Regarding short-term risk, GLASF is less volatile compared to SGFEF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check SGFEF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HKMPY has a market cap of 4.1B. Regarding current trading prices, GLASF is priced at $9.65, while HKMPY trades at $37.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HKMPY's P/E ratio is 10.28. In terms of profitability, GLASF's ROE is -0.23%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, GLASF is more volatile compared to HKMPY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HKMPY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HKMPF has a market cap of 3.9B. Regarding current trading prices, GLASF is priced at $9.65, while HKMPF trades at $18.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HKMPF's P/E ratio is 10.00. In terms of profitability, GLASF's ROE is -0.23%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, GLASF is more volatile compared to HKMPF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HKMPF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, APNHF has a market cap of 3.9B. Regarding current trading prices, GLASF is priced at $9.65, while APNHF trades at $8.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas APNHF's P/E ratio is -34.76. In terms of profitability, GLASF's ROE is -0.23%, compared to APNHF's ROE of -0.02%. Regarding short-term risk, GLASF is more volatile compared to APNHF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check APNHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, APNHY has a market cap of 3.6B. Regarding current trading prices, GLASF is priced at $9.65, while APNHY trades at $8.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas APNHY's P/E ratio is -32.16. In terms of profitability, GLASF's ROE is -0.23%, compared to APNHY's ROE of -0.02%. Regarding short-term risk, GLASF is less volatile compared to APNHY. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check APNHY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, LBTSF has a market cap of 3.3B. Regarding current trading prices, GLASF is priced at $9.65, while LBTSF trades at $15.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas LBTSF's P/E ratio is 59.04. In terms of profitability, GLASF's ROE is -0.23%, compared to LBTSF's ROE of +0.04%. Regarding short-term risk, GLASF is more volatile compared to LBTSF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check LBTSF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CHSYF has a market cap of 3.3B. Regarding current trading prices, GLASF is priced at $9.65, while CHSYF trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CHSYF's P/E ratio is 13.50. In terms of profitability, GLASF's ROE is -0.23%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, GLASF is less volatile compared to CHSYF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CHSYF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HYPMY has a market cap of 3.3B. Regarding current trading prices, GLASF is priced at $9.65, while HYPMY trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HYPMY's P/E ratio is 8.91. In terms of profitability, GLASF's ROE is -0.23%, compared to HYPMY's ROE of +0.13%. Regarding short-term risk, GLASF is more volatile compared to HYPMY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HYPMY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, GLASF is priced at $9.65, while INVVY trades at $21.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas INVVY's P/E ratio is -62.42. In terms of profitability, GLASF's ROE is -0.23%, compared to INVVY's ROE of -0.42%. Regarding short-term risk, GLASF is more volatile compared to INVVY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check INVVY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, GLASF is priced at $9.65, while IZQVF trades at $20.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, GLASF's ROE is -0.23%, compared to IZQVF's ROE of -0.99%. Regarding short-term risk, GLASF is more volatile compared to IZQVF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check IZQVF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CURLF has a market cap of 2.5B. Regarding current trading prices, GLASF is priced at $9.65, while CURLF trades at $3.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CURLF's P/E ratio is -10.19. In terms of profitability, GLASF's ROE is -0.23%, compared to CURLF's ROE of -0.29%. Regarding short-term risk, GLASF is less volatile compared to CURLF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CURLF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HMDCF has a market cap of 2.4B. Regarding current trading prices, GLASF is priced at $9.65, while HMDCF trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HMDCF's P/E ratio is 5.32. In terms of profitability, GLASF's ROE is -0.23%, compared to HMDCF's ROE of +0.41%. Regarding short-term risk, GLASF is less volatile compared to HMDCF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check HMDCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ULIHF has a market cap of 2.3B. Regarding current trading prices, GLASF is priced at $9.65, while ULIHF trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ULIHF's P/E ratio is 7.44. In terms of profitability, GLASF's ROE is -0.23%, compared to ULIHF's ROE of +0.13%. Regarding short-term risk, GLASF is less volatile compared to ULIHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check ULIHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, NPPNY has a market cap of 2.2B. Regarding current trading prices, GLASF is priced at $9.65, while NPPNY trades at $8.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas NPPNY's P/E ratio is 11.01. In terms of profitability, GLASF's ROE is -0.23%, compared to NPPNY's ROE of +0.12%. Regarding short-term risk, GLASF is less volatile compared to NPPNY. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check NPPNY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, GLASF is priced at $9.65, while DMPHF trades at $39.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas DMPHF's P/E ratio is 17.90. In terms of profitability, GLASF's ROE is -0.23%, compared to DMPHF's ROE of +0.20%. Regarding short-term risk, GLASF is less volatile compared to DMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check DMPHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, NPNKF has a market cap of 2.1B. Regarding current trading prices, GLASF is priced at $9.65, while NPNKF trades at $31.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas NPNKF's P/E ratio is 10.57. In terms of profitability, GLASF's ROE is -0.23%, compared to NPNKF's ROE of +0.11%. Regarding short-term risk, GLASF is less volatile compared to NPNKF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check NPNKF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HTSUF has a market cap of 2B. Regarding current trading prices, GLASF is priced at $9.65, while HTSUF trades at $29.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HTSUF's P/E ratio is 16.76. In terms of profitability, GLASF's ROE is -0.23%, compared to HTSUF's ROE of +0.07%. Regarding short-term risk, GLASF is more volatile compared to HTSUF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HTSUF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ARSUF has a market cap of 1.9B. Regarding current trading prices, GLASF is priced at $9.65, while ARSUF trades at $26.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ARSUF's P/E ratio is 18.30. In terms of profitability, GLASF's ROE is -0.23%, compared to ARSUF's ROE of +0.17%. Regarding short-term risk, GLASF is more volatile compared to ARSUF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check ARSUF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, DUTV has a market cap of 1.9B. Regarding current trading prices, GLASF is priced at $9.65, while DUTV trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas DUTV's P/E ratio is N/A. In terms of profitability, GLASF's ROE is -0.23%, compared to DUTV's ROE of -0.04%. Regarding short-term risk, GLASF is less volatile compared to DUTV. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check DUTV's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, GTBIF has a market cap of 1.8B. Regarding current trading prices, GLASF is priced at $9.65, while GTBIF trades at $8.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas GTBIF's P/E ratio is 16.23. In terms of profitability, GLASF's ROE is -0.23%, compared to GTBIF's ROE of +0.06%. Regarding short-term risk, GLASF is less volatile compared to GTBIF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check GTBIF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TCNNF has a market cap of 1.8B. Regarding current trading prices, GLASF is priced at $9.65, while TCNNF trades at $9.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TCNNF's P/E ratio is -15.90. In terms of profitability, GLASF's ROE is -0.23%, compared to TCNNF's ROE of -0.10%. Regarding short-term risk, GLASF is less volatile compared to TCNNF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check TCNNF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TSMRF has a market cap of 1.7B. Regarding current trading prices, GLASF is priced at $9.65, while TSMRF trades at $23.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TSMRF's P/E ratio is 10.04. In terms of profitability, GLASF's ROE is -0.23%, compared to TSMRF's ROE of +0.10%. Regarding short-term risk, GLASF is less volatile compared to TSMRF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check TSMRF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SHPHF has a market cap of 1.7B. Regarding current trading prices, GLASF is priced at $9.65, while SHPHF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SHPHF's P/E ratio is -6.22. In terms of profitability, GLASF's ROE is -0.23%, compared to SHPHF's ROE of +0.03%. Regarding short-term risk, GLASF is more volatile compared to SHPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SHPHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, GLASF is priced at $9.65, while MITPF trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas MITPF's P/E ratio is -10.81. In terms of profitability, GLASF's ROE is -0.23%, compared to MITPF's ROE of +4.99%. Regarding short-term risk, GLASF is less volatile compared to MITPF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check MITPF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, GLASF is priced at $9.65, while KARBF trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas KARBF's P/E ratio is 262.50. In terms of profitability, GLASF's ROE is -0.23%, compared to KARBF's ROE of N/A. Regarding short-term risk, GLASF is more volatile compared to KARBF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check KARBF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CASBF has a market cap of 1.3B. Regarding current trading prices, GLASF is priced at $9.65, while CASBF trades at $3.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CASBF's P/E ratio is 193.00. In terms of profitability, GLASF's ROE is -0.23%, compared to CASBF's ROE of -0.00%. Regarding short-term risk, GLASF is less volatile compared to CASBF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CASBF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SWGHF has a market cap of 1.3B. Regarding current trading prices, GLASF is priced at $9.65, while SWGHF trades at $11.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, GLASF's ROE is -0.23%, compared to SWGHF's ROE of +0.05%. Regarding short-term risk, GLASF is more volatile compared to SWGHF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SWGHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, LJUIF has a market cap of 1.2B. Regarding current trading prices, GLASF is priced at $9.65, while LJUIF trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas LJUIF's P/E ratio is 13.42. In terms of profitability, GLASF's ROE is -0.23%, compared to LJUIF's ROE of +0.06%. Regarding short-term risk, GLASF is less volatile compared to LJUIF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check LJUIF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, BIOGY has a market cap of 1.1B. Regarding current trading prices, GLASF is priced at $9.65, while BIOGY trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas BIOGY's P/E ratio is 31.43. In terms of profitability, GLASF's ROE is -0.23%, compared to BIOGY's ROE of +0.24%. Regarding short-term risk, GLASF is more volatile compared to BIOGY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check BIOGY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CHIZF has a market cap of 1.1B. Regarding current trading prices, GLASF is priced at $9.65, while CHIZF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CHIZF's P/E ratio is -21.89. In terms of profitability, GLASF's ROE is -0.23%, compared to CHIZF's ROE of -0.01%. Regarding short-term risk, GLASF is more volatile compared to CHIZF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check CHIZF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, KSPHF has a market cap of 1.1B. Regarding current trading prices, GLASF is priced at $9.65, while KSPHF trades at $25.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas KSPHF's P/E ratio is 12.04. In terms of profitability, GLASF's ROE is -0.23%, compared to KSPHF's ROE of +0.07%. Regarding short-term risk, GLASF is less volatile compared to KSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check KSPHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, GNMLF has a market cap of 1.1B. Regarding current trading prices, GLASF is priced at $9.65, while GNMLF trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas GNMLF's P/E ratio is 12.00. In terms of profitability, GLASF's ROE is -0.23%, compared to GNMLF's ROE of +0.08%. Regarding short-term risk, GLASF is less volatile compared to GNMLF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check GNMLF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, KKPCF has a market cap of 984.6M. Regarding current trading prices, GLASF is priced at $9.65, while KKPCF trades at $26.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas KKPCF's P/E ratio is 288.89. In terms of profitability, GLASF's ROE is -0.23%, compared to KKPCF's ROE of -0.03%. Regarding short-term risk, GLASF is less volatile compared to KKPCF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check KKPCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, EVOTF has a market cap of 930.6M. Regarding current trading prices, GLASF is priced at $9.65, while EVOTF trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas EVOTF's P/E ratio is -7.71. In terms of profitability, GLASF's ROE is -0.23%, compared to EVOTF's ROE of -0.12%. Regarding short-term risk, GLASF is less volatile compared to EVOTF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check EVOTF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, GLASF is priced at $9.65, while TWAPF trades at $16.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TWAPF's P/E ratio is 6.28. In terms of profitability, GLASF's ROE is -0.23%, compared to TWAPF's ROE of +0.12%. Regarding short-term risk, GLASF is less volatile compared to TWAPF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check TWAPF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CSWYF has a market cap of 758.4M. Regarding current trading prices, GLASF is priced at $9.65, while CSWYF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CSWYF's P/E ratio is 4.78. In terms of profitability, GLASF's ROE is -0.23%, compared to CSWYF's ROE of +0.12%. Regarding short-term risk, GLASF is less volatile compared to CSWYF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CSWYF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, GLASF is priced at $9.65, while TRXPF trades at $24.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, GLASF's ROE is -0.23%, compared to TRXPF's ROE of +0.03%. Regarding short-term risk, GLASF is more volatile compared to TRXPF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check TRXPF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SHEZF has a market cap of 689M. Regarding current trading prices, GLASF is priced at $9.65, while SHEZF trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, GLASF's ROE is -0.23%, compared to SHEZF's ROE of +0.03%. Regarding short-term risk, GLASF is less volatile compared to SHEZF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check SHEZF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, YIHCF has a market cap of 643.1M. Regarding current trading prices, GLASF is priced at $9.65, while YIHCF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, GLASF's ROE is -0.23%, compared to YIHCF's ROE of +0.06%. Regarding short-term risk, GLASF is more volatile compared to YIHCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check YIHCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, AIHLF has a market cap of 624.3M. Regarding current trading prices, GLASF is priced at $9.65, while AIHLF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas AIHLF's P/E ratio is 10.94. In terms of profitability, GLASF's ROE is -0.23%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, GLASF is more volatile compared to AIHLF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check AIHLF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, GLASF is priced at $9.65, while TRSSF trades at $1.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, GLASF's ROE is -0.23%, compared to TRSSF's ROE of -0.68%. Regarding short-term risk, GLASF is less volatile compared to TRSSF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check TRSSF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, AGYTF has a market cap of 554.6M. Regarding current trading prices, GLASF is priced at $9.65, while AGYTF trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas AGYTF's P/E ratio is -11.00. In terms of profitability, GLASF's ROE is -0.23%, compared to AGYTF's ROE of +2.84%. Regarding short-term risk, GLASF is more volatile compared to AGYTF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check AGYTF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, PKBFF has a market cap of 544.7M. Regarding current trading prices, GLASF is priced at $9.65, while PKBFF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas PKBFF's P/E ratio is N/A. In terms of profitability, GLASF's ROE is -0.23%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, GLASF is more volatile compared to PKBFF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check PKBFF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, KHTRF has a market cap of 529.6M. Regarding current trading prices, GLASF is priced at $9.65, while KHTRF trades at $5.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas KHTRF's P/E ratio is -135.05. In terms of profitability, GLASF's ROE is -0.23%, compared to KHTRF's ROE of -0.01%. Regarding short-term risk, GLASF is less volatile compared to KHTRF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check KHTRF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, GLASF is priced at $9.65, while CCHWF trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, GLASF's ROE is -0.23%, compared to CCHWF's ROE of +0.42%. Regarding short-term risk, GLASF is less volatile compared to CCHWF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CCHWF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, BOIRF has a market cap of 520.9M. Regarding current trading prices, GLASF is priced at $9.65, while BOIRF trades at $30.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas BOIRF's P/E ratio is 22.73. In terms of profitability, GLASF's ROE is -0.23%, compared to BOIRF's ROE of +0.05%. Regarding short-term risk, GLASF is more volatile compared to BOIRF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check BOIRF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, VRNOF has a market cap of 470.4M. Regarding current trading prices, GLASF is priced at $9.65, while VRNOF trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas VRNOF's P/E ratio is -1.31. In terms of profitability, GLASF's ROE is -0.23%, compared to VRNOF's ROE of -0.31%. Regarding short-term risk, GLASF is less volatile compared to VRNOF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check VRNOF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, GLASF is priced at $9.65, while PEXXF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, GLASF's ROE is -0.23%, compared to PEXXF's ROE of N/A. Regarding short-term risk, GLASF is more volatile compared to PEXXF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check PEXXF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HUMDF has a market cap of 430.9M. Regarding current trading prices, GLASF is priced at $9.65, while HUMDF trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HUMDF's P/E ratio is 2.70. In terms of profitability, GLASF's ROE is -0.23%, compared to HUMDF's ROE of +1.07%. Regarding short-term risk, GLASF is less volatile compared to HUMDF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check HUMDF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, NIKA has a market cap of 421.1M. Regarding current trading prices, GLASF is priced at $9.65, while NIKA trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas NIKA's P/E ratio is N/A. In terms of profitability, GLASF's ROE is -0.23%, compared to NIKA's ROE of +0.29%. Regarding short-term risk, GLASF is less volatile compared to NIKA. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check NIKA's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SWDCF has a market cap of 399.6M. Regarding current trading prices, GLASF is priced at $9.65, while SWDCF trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SWDCF's P/E ratio is 83.33. In terms of profitability, GLASF's ROE is -0.23%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, GLASF is less volatile compared to SWDCF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check SWDCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ELTP has a market cap of 372.6M. Regarding current trading prices, GLASF is priced at $9.65, while ELTP trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ELTP's P/E ratio is 8.65. In terms of profitability, GLASF's ROE is -0.23%, compared to ELTP's ROE of +0.71%. Regarding short-term risk, GLASF is less volatile compared to ELTP. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check ELTP's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CRLBF has a market cap of 352M. Regarding current trading prices, GLASF is priced at $9.65, while CRLBF trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CRLBF's P/E ratio is -2.70. In terms of profitability, GLASF's ROE is -0.23%, compared to CRLBF's ROE of -0.33%. Regarding short-term risk, GLASF is less volatile compared to CRLBF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CRLBF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CPHRF has a market cap of 333.6M. Regarding current trading prices, GLASF is priced at $9.65, while CPHRF trades at $13.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CPHRF's P/E ratio is 12.57. In terms of profitability, GLASF's ROE is -0.23%, compared to CPHRF's ROE of +0.24%. Regarding short-term risk, GLASF is more volatile compared to CPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check CPHRF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, BHCCF has a market cap of 225.1M. Regarding current trading prices, GLASF is priced at $9.65, while BHCCF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, GLASF's ROE is -0.23%, compared to BHCCF's ROE of +0.29%. Regarding short-term risk, GLASF is less volatile compared to BHCCF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check BHCCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, GLASF is priced at $9.65, while PLNHF trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, GLASF's ROE is -0.23%, compared to PLNHF's ROE of +659479.06%. Regarding short-term risk, GLASF is less volatile compared to PLNHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check PLNHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, PHCUF has a market cap of 188.1M. Regarding current trading prices, GLASF is priced at $9.65, while PHCUF trades at $7.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas PHCUF's P/E ratio is -707.00. In terms of profitability, GLASF's ROE is -0.23%, compared to PHCUF's ROE of -0.00%. Regarding short-term risk, GLASF is more volatile compared to PHCUF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check PHCUF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, SHIEF has a market cap of 179.4M. Regarding current trading prices, GLASF is priced at $9.65, while SHIEF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas SHIEF's P/E ratio is -8.39. In terms of profitability, GLASF's ROE is -0.23%, compared to SHIEF's ROE of +1.01%. Regarding short-term risk, GLASF is more volatile compared to SHIEF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check SHIEF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CBWTF has a market cap of 139.2M. Regarding current trading prices, GLASF is priced at $9.65, while CBWTF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CBWTF's P/E ratio is 4.96. In terms of profitability, GLASF's ROE is -0.23%, compared to CBWTF's ROE of +0.23%. Regarding short-term risk, GLASF is less volatile compared to CBWTF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CBWTF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, GLASF is priced at $9.65, while COPHF trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas COPHF's P/E ratio is -0.02. In terms of profitability, GLASF's ROE is -0.23%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, GLASF is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check COPHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, LOVFF has a market cap of 126.4M. Regarding current trading prices, GLASF is priced at $9.65, while LOVFF trades at $1.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas LOVFF's P/E ratio is 16.00. In terms of profitability, GLASF's ROE is -0.23%, compared to LOVFF's ROE of +0.09%. Regarding short-term risk, GLASF is less volatile compared to LOVFF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check LOVFF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, NWPN has a market cap of 123.7M. Regarding current trading prices, GLASF is priced at $9.65, while NWPN trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas NWPN's P/E ratio is -0.04. In terms of profitability, GLASF's ROE is -0.23%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, GLASF is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check NWPN's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, BIOYF has a market cap of 122.2M. Regarding current trading prices, GLASF is priced at $9.65, while BIOYF trades at $10.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas BIOYF's P/E ratio is 18.65. In terms of profitability, GLASF's ROE is -0.23%, compared to BIOYF's ROE of +0.23%. Regarding short-term risk, GLASF is more volatile compared to BIOYF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check BIOYF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, LPCUF has a market cap of 112.1M. Regarding current trading prices, GLASF is priced at $9.65, while LPCUF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas LPCUF's P/E ratio is 9.51. In terms of profitability, GLASF's ROE is -0.23%, compared to LPCUF's ROE of +0.06%. Regarding short-term risk, GLASF is less volatile compared to LPCUF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check LPCUF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, GLASF is priced at $9.65, while CNVCF trades at $6.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, GLASF's ROE is -0.23%, compared to CNVCF's ROE of +1.21%. Regarding short-term risk, GLASF is more volatile compared to CNVCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check CNVCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, HLTRF has a market cap of 107.6M. Regarding current trading prices, GLASF is priced at $9.65, while HLTRF trades at $3.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas HLTRF's P/E ratio is -8.82. In terms of profitability, GLASF's ROE is -0.23%, compared to HLTRF's ROE of -0.19%. Regarding short-term risk, GLASF is more volatile compared to HLTRF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check HLTRF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, AAWH has a market cap of 107.2M. Regarding current trading prices, GLASF is priced at $9.65, while AAWH trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas AAWH's P/E ratio is -0.91. In terms of profitability, GLASF's ROE is -0.23%, compared to AAWH's ROE of -14.10%. Regarding short-term risk, GLASF is more volatile compared to AAWH. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check AAWH's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, JUSHF has a market cap of 99.8M. Regarding current trading prices, GLASF is priced at $9.65, while JUSHF trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas JUSHF's P/E ratio is -1.43. In terms of profitability, GLASF's ROE is -0.23%, compared to JUSHF's ROE of +0.76%. Regarding short-term risk, GLASF is less volatile compared to JUSHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check JUSHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, MEDXF has a market cap of 90.8M. Regarding current trading prices, GLASF is priced at $9.65, while MEDXF trades at $2.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas MEDXF's P/E ratio is -140.50. In terms of profitability, GLASF's ROE is -0.23%, compared to MEDXF's ROE of -0.01%. Regarding short-term risk, GLASF is less volatile compared to MEDXF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check MEDXF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, GRUSF has a market cap of 90M. Regarding current trading prices, GLASF is priced at $9.65, while GRUSF trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas GRUSF's P/E ratio is 36.00. In terms of profitability, GLASF's ROE is -0.23%, compared to GRUSF's ROE of +0.00%. Regarding short-term risk, GLASF is less volatile compared to GRUSF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check GRUSF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, CWBHF has a market cap of 85.1M. Regarding current trading prices, GLASF is priced at $9.65, while CWBHF trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas CWBHF's P/E ratio is -2.79. In terms of profitability, GLASF's ROE is -0.23%, compared to CWBHF's ROE of -2.75%. Regarding short-term risk, GLASF is less volatile compared to CWBHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check CWBHF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ABSCF has a market cap of 74.1M. Regarding current trading prices, GLASF is priced at $9.65, while ABSCF trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ABSCF's P/E ratio is -6.22. In terms of profitability, GLASF's ROE is -0.23%, compared to ABSCF's ROE of +0.33%. Regarding short-term risk, GLASF is more volatile compared to ABSCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check ABSCF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ORXOF has a market cap of 73.8M. Regarding current trading prices, GLASF is priced at $9.65, while ORXOF trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ORXOF's P/E ratio is -1.62. In terms of profitability, GLASF's ROE is -0.23%, compared to ORXOF's ROE of -2.28%. Regarding short-term risk, GLASF is less volatile compared to ORXOF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check ORXOF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, GLASF is priced at $9.65, while EOFBY trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, GLASF's ROE is -0.23%, compared to EOFBY's ROE of -0.77%. Regarding short-term risk, GLASF is more volatile compared to EOFBY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check EOFBY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, ORXOY has a market cap of 71.8M. Regarding current trading prices, GLASF is priced at $9.65, while ORXOY trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas ORXOY's P/E ratio is -1.64. In terms of profitability, GLASF's ROE is -0.23%, compared to ORXOY's ROE of -2.28%. Regarding short-term risk, GLASF is more volatile compared to ORXOY. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check ORXOY's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, VEXTF has a market cap of 64M. Regarding current trading prices, GLASF is priced at $9.65, while VEXTF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas VEXTF's P/E ratio is -3.69. In terms of profitability, GLASF's ROE is -0.23%, compared to VEXTF's ROE of -0.27%. Regarding short-term risk, GLASF is less volatile compared to VEXTF. This indicates potentially lower risk in terms of short-term price fluctuations for GLASF.Check VEXTF's competition here

GLASF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLASF stands at 713.9M. In comparison, GDNSF has a market cap of 61M. Regarding current trading prices, GLASF is priced at $9.65, while GDNSF trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLASF currently has a P/E ratio of -16.76, whereas GDNSF's P/E ratio is -2.66. In terms of profitability, GLASF's ROE is -0.23%, compared to GDNSF's ROE of -0.69%. Regarding short-term risk, GLASF is more volatile compared to GDNSF. This indicates potentially higher risk in terms of short-term price fluctuations for GLASF.Check GDNSF's competition here